Buch, Englisch, Band 186, 328 Seiten, HC runder Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 738 g
Buch, Englisch, Band 186, 328 Seiten, HC runder Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 738 g
Reihe: Cancer Treatment and Research
ISBN: 978-3-031-30064-6
Verlag: Springer International Publishing
Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Naturwissenschaften Physik Angewandte Physik Medizinische Physik
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
Weitere Infos & Material
Evolution of the development of PARP inhibitors.- Exploiting cancer synthetic lethality in cancer – Lessons learnt from PARP inhibitors.- Mechanisms of PARP inhibitor resistance.- Development of homologous recombination functional assays for targeting the DDR.- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer.- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer.- Development of PARP inhibitors in targeting castration-resistant prostate cancer.- Strategies for the management of patients with pancreatic cancer with PARP inhibitors.- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges.- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents.- Combining PARP inhibition and immunotherapy in BRCA-associated cancers.- Mitotic MTH1 inhibitors in treatment of cancer.- Targeting ATR in cancer medicine.- Targeting polymerase Theta (POLq) for cancer therapy.- Targeting DNA-PK.- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI).